Table 3.
Univariate analysis of locoregional control rates
| Variables | LC | |||
|---|---|---|---|---|
| One-year (%) | Two-year (%) | p | ||
| Age | < 65 years (n = 10) | 79 | 53 | 0.5625 |
| ≥ 65 years (n = 11) | 58 | 58 | ||
| Sex | male (n = 8) | 75 | 60 | 0.9379 |
| female (n = 13) | 64 | 51 | ||
| Pittsburgh staging | T3 (n = 10) | 79 | 79 | 0.1862 |
| T4 (n = 11) | 57 | 34 | ||
| Neurological findings before treatment | yes (n = 8) | 58 | 58 | 0.6727 |
| no (n = 13) | 75 | 54 | ||
| Surgery | yes (n = 13) | 65 | 43 | 0.7230 |
| no (n = 8) | 75 | 75 | ||
| Systemic therapy | yes (n = 9) | 65 | 65 | 0.7374 |
| no (n = 12) | 73 | 36 | ||
| Radiation dose (Gy) | < 66 Gy (n = 4) | 38 | - | 0.3707 |
| ≥ 66 Gy (n = 17) | 74 | 60 | ||
| Irradiated field | local (n = 12) | 52 | 35 | 0.0560 |
| local + prophylactic (n = 9) | 89 | 76 | ||
| NLR | < 4.43 (n = 17) | 69 | 53 | 0.9018 |
| ≥ 4.43 (n = 4) | 75 | 75 | ||
| CAR | < 0.31 (n = 16) | 87 | 69 | 0.0035 |
| ≥ 0.31 (n = 5) | 0 | 0 | ||
| PLR | < 135.9 (n = 8) | 88 | 58 | 0.8190 |
| ≥ 135.9 (n = 13) | 53 | 53 | ||
| AGR | < 1.40 (n = 13) | 59 | 39 | 0.0792 |
| ≥ 1.40 (n = 8) | 86 | 86 | ||
LC; locoregional control, NLR; neutrophil-to-lymphocyte ratio, CAR; C-reactive protein-to-albumin ratio, PLR; platelet-to-lymphocyte ratio, AGR; albumin-to-globulin ratio.